» Articles » PMID: 27453753

The Multimodal Management of GH-secreting Pituitary Adenomas: Predictive Factors, Strategies and Outcomes

Overview
Journal J Med Life
Specialty General Medicine
Date 2016 Jul 26
PMID 27453753
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Object. The aim of this study was to analyze a series of 28 patients with acromegaly who underwent a multimodal surgical, medical and radiosurgical therapy, with a special attention to the advantages, complications, and predictive factors of a successful outcome. Methods. 28 consecutive cases of GH-secreting pituitary adenomas, who underwent transsphenoidal endoscopic or microscopic surgery, between 1 January 2014 and 31 December 2014 were retrospectively reviewed. Tumors were classified according to the diameter, measured on MRI, as micro- or macroadenomas, and parasellar (cavernous sinus) tumor extension was analyzed based on the Knosp grading score. The mean follow-up period was of 18.4 months. Criteria justifying the complete hormonal remission were preoperative basal serum GH < 2.5 μg/ L, preoperative nadirGH < 1 ng/ L after OGTT and normal preoperative IGF-I levels age and sex-matched. Results. An overall complete hormonal remission rate was achieved in 64.3% of the patients. The remission rate was higher in patients with microadenomas (77.8%) than in those with macroadenomas (57.9%). A number of predictive factors, which might have interfered with the hormonal remission rate from a statistical, clinical and paraclinical point of view, were identified: tumor size (r = 0.625), preoperative GH serum levels (r = -0.517), cavernous sinus extension was quantified according to Knosp grading score (r = 0.469) and the degree of tumor subtotal resection (r = 0.598). Conclusions. Favorable hormonal and visual remission rates can be achieved after transsphenoidal resection of GH-secreting pituitary adenomas; however, the management remains challenging, the increased surgical experience being important for higher cure rates. If a biochemical hormonal cure is not achieved postoperatively, adjuvant medical or radio surgical therapy can be recommended.

Citing Articles

Outcomes in pituitary adenoma causing acromegaly following endoscopic endonasal transsphenoidal surgery.

Chhabra R, Kumar A, Virk R, Dutta P, Ahuja C, Mohanty M J Neurosci Rural Pract. 2023; 13(4):696-704.

PMID: 36743751 PMC: 9894003. DOI: 10.25259/JNRP-2022-3-28-R1-(2453).


The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up.

Ferres A, Reyes L, Di Somma A, Topczewski T, Mosteiro A, Guizzardi G Cancers (Basel). 2023; 15(1).

PMID: 36612263 PMC: 9818833. DOI: 10.3390/cancers15010267.


GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil.

Manosso K, Sampaio C, Kasuki L, Antunes X, Gadelha M, Boguszewski C Endocrine. 2021; 74(1):146-154.

PMID: 34041695 DOI: 10.1007/s12020-021-02766-2.


Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review.

Serioli S, Doglietto F, Fiorindi A, Biroli A, Mattavelli D, Buffoli B Cancers (Basel). 2019; 11(12).

PMID: 31817110 PMC: 6966643. DOI: 10.3390/cancers11121936.


Development and assessment of machine learning algorithms for predicting remission after transsphenoidal surgery among patients with acromegaly.

Fan Y, Li Y, Li Y, Feng S, Bao X, Feng M Endocrine. 2019; 67(2):412-422.

PMID: 31673954 DOI: 10.1007/s12020-019-02121-6.


References
1.
Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, Hubalewska-Dydejczyk A . Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary. 2010; 14(2):157-62. PMC: 3094540. DOI: 10.1007/s11102-010-0273-0. View

2.
Choe J, Lee K, Jeun S, Cho J, Hong Y . Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas. J Korean Neurosurg Soc. 2008; 44(3):151-5. PMC: 2588303. DOI: 10.3340/jkns.2008.44.3.151. View

3.
Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H . Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005; 152(1):61-6. DOI: 10.1530/eje.1.01824. View

4.
Ross D, Wilson C . Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 1988; 68(6):854-67. DOI: 10.3171/jns.1988.68.6.0854. View

5.
Karavitaki N, Turner H, Adams C, Cudlip S, Byrne J, Fazal-Sanderson V . Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf). 2007; 68(6):970-5. DOI: 10.1111/j.1365-2265.2007.03139.x. View